Antibodies to PECAM-1 and glucocorticoids reduce leukocyte adhesion in adjuvant arthritis of the rat knee synovium in vivo

被引:6
作者
Decking, J
Mayer, A
Petrow, P
Seiffge, D
Karbowski, A
机构
[1] Univ Mainz, Dept Orthopaed Surg, DE-55101 Mainz, Germany
[2] Univ Mainz, Inst Pathol, D-6500 Mainz, Germany
[3] Aventis Pharma Deutschland GmbH, Frankfurt, Germany
[4] Krankenhaus Augustinerinnen, Dept Orthopaed Surg, Cologne, Germany
关键词
PECAM-1; adhesion molecules; rheumatoid arthritis; confocal laser scanning microscopy; adjuvant arthritis;
D O I
10.1007/PL00000242
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and design: To demonstrate the effect of monoclonal antibodies to the adhesion-molecule PECAM-1 (CD31) and of prednisolone on leukocyte adhesion in rat adjuvant arthritis. Material: Adjuvant arthritis was induced in male CU(R)-rats (five groups of n=6) 18 days prior to measurements. Treatment: Mouse-monoclonal antibody to rat CD-31 at 200 mug/kg or prednisolone at 24 mg/kg were administered i.v. 15 minutes prior to measurements. Methods: Venules within the intact rat-knee synovium were focused by confocal laser scanning microscopy. Numbers of rolling and adherent leukocytes were assessed in vivo. Results: Induction of arthritis significantly increased rolling and adherent leukocytes compared to healthy controls. Both monoclonal antibodies to PECAM-1 and prednisolone significantly reduced adherent, but not rolling leukocytes in arthritic animals. Conclusions: The method used is well suited for in vivo quantification of leukocyte adhesion under the influence of antiadhesive therapies. PECAM-1 might be an interesting target for novel therapies in rheumatoid arthritis.
引用
收藏
页码:609 / 615
页数:7
相关论文
共 36 条
[1]   MOLECULAR AND CELLULAR PROPERTIES OF PECAM-1 (ENDOCAM/CD31) - A NOVEL VASCULAR CELL CELL-ADHESION MOLECULE [J].
ALBELDA, SM ;
MULLER, WA ;
BUCK, CA ;
NEWMAN, PJ .
JOURNAL OF CELL BIOLOGY, 1991, 114 (05) :1059-1068
[2]   Antibodies to tumour necrosis factor α as treatment for Crohn's disease [J].
Bell, S ;
Kamm, MA .
LANCET, 2000, 355 (9207) :858-860
[3]  
BERMAN ME, 1995, J IMMUNOL, V154, P299
[4]  
Berman ME, 1996, J IMMUNOL, V156, P1515
[5]  
Billingham M.E.J., 1995, MECH MODELS RHEUMATO, V20, P389
[6]   MONOCLONAL-ANTIBODY TO MURINE PECAM-1 (CD31) BLOCKS ACUTE-INFLAMMATION IN-VIVO [J].
BOGEN, S ;
PAK, J ;
GARIFALLOU, M ;
DENG, XH ;
MULLER, WA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :1059-1064
[7]  
Buckley CD, 1996, J CELL SCI, V109, P437
[8]  
ChristofidouSolomidou M, 1997, J IMMUNOL, V158, P4872
[9]  
Davenpeck KL, 1998, J IMMUNOL, V161, P6861
[10]   MOLECULAR AND FUNCTIONAL-ASPECTS OF PECAM-1 CD31 [J].
DELISSER, HM ;
NEWMAN, PJ ;
ALBELDA, SM .
IMMUNOLOGY TODAY, 1994, 15 (10) :490-495